{
    "clinical_study": {
        "@rank": "104207", 
        "arm_group": [
            {
                "arm_group_label": "Hemodiafiltration, NaCl infusion", 
                "arm_group_type": "Experimental", 
                "description": "5 M NaCl solution will be infused to increase the NaCl concentration in the infusion fluid during predilution hemodiafiltration."
            }, 
            {
                "arm_group_label": "Hemodialysis", 
                "arm_group_type": "No Intervention"
            }, 
            {
                "arm_group_label": "Hemodiafiltration", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "An increase of the free fraction may allow a better removal of of protein-bound uremic\n      toxins during dialysis. During predilution hemodiafiltration, the sodium chloride (NaCl)\n      concentration will be increased in the infusion fluid at a target NaCl concentration and the\n      effect on the removal of protein-bound toxins will be determined. Comparisons will be made\n      to standard hemodialysis and hemodiafiltration."
        }, 
        "brief_title": "Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "End-stage Renal Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  End-stage renal disease\n\n          -  Maintenance hemodialysis or hemodiafiltration for more than 3 months\n\n          -  Stable clinical condition\n\n          -  > 18 years\n\n        Exclusion Criteria:\n\n          -  Life expectancy less than 1 year\n\n          -  Pregnancy\n\n          -  Active infectious disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01923961", 
            "org_study_id": "KSSA0113"
        }, 
        "intervention": {
            "arm_group_label": "Hemodiafiltration, NaCl infusion", 
            "description": "Infusion of 5 M NaCl adjusted at target NaCl concentration in plasma.", 
            "intervention_name": "5 M NaCl solution", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Maintenance hemodialysis or hemodiafiltration", 
            ">18 years", 
            "Stable condition"
        ], 
        "lastchanged_date": "August 14, 2013", 
        "location": {
            "contact": {
                "last_name": "Andreas Morgenroth, MD", 
                "phone": "+49-6022", 
                "phone_ext": "2655655"
            }, 
            "facility": {
                "address": {
                    "city": "Elsenfeld", 
                    "country": "Germany", 
                    "state": "Bavaria", 
                    "zip": "63820"
                }, 
                "name": "Dialysis Center Elsenfeld"
            }, 
            "investigator": {
                "last_name": "Detlef H Krieter, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Impact of an Increased Sodium Chloride Concentration in the Infusion Fluid of Predilution Hemodiafiltration on the Removal of Protein-Bound Uremic Toxins", 
        "other_outcome": {
            "description": "Determination of the course of hemocompatibility parameters", 
            "measure": "Plasma concentrations of blood cells, complement C5a, thrombin-antithrombin III, and free hemoglobin", 
            "safety_issue": "Yes", 
            "time_frame": "4 hours"
        }, 
        "overall_contact": {
            "email": "krieter_d@medizin.uni-wuerzburg.de", 
            "last_name": "Detlef H Krieter, MD", 
            "phone": "+49-931-201", 
            "phone_ext": "39030"
        }, 
        "overall_official": {
            "affiliation": "University Hospital W\u00fcrzburg", 
            "last_name": "Detlef H Krieter, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determination of performance; calculation of removal ratios, clearances, and mass balances of protein-bound uremic toxins", 
            "measure": "Plasma concentrations of para-cresylsulfate and indoxylsulfate", 
            "safety_issue": "No", 
            "time_frame": "4 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01923961"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measurement of NaCl concentrations over time to verify adequate NaCl balance", 
            "measure": "Plasma concentrations of NaCl", 
            "safety_issue": "Yes", 
            "time_frame": "4 hours"
        }, 
        "source": "EXcorLab GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EXcorLab GmbH", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}